Navigation Links
WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
Date:3/13/2013

SHANGHAI, March 13, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its Suzhou toxicology facility had received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) after an extensive on-site evaluation. The AAALAC Committee on Accreditation commended the facility for "providing and maintaining an exemplary program of animal care." This represents AAALAC's highest level of commendation. The Suzhou facility first received accreditation from AAALAC in February 2010.

AAALAC is a private, nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. It evaluates all aspects of an animal care and use program, including institutional policies, animal husbandry, veterinary care and the physical plant. In its evaluations, it relies on widely accepted guidelines, such as the Guide for the Care and Use of Laboratory Animals and other reference resources, as well as its own position statements and Rules of Accreditation.

For more information, please contact:

Ronald Aldridge (for investors)
Tel:   +1-201-585-2048
Email: ir@wuxiapptec.com

Aaron Shi (for the media)
Tel:   +86-21-5046-4362
Email: pr@wuxiapptec.com

Web: http://www.wuxiapptec.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
2. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
3. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
4. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
5. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
6. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
7. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
8. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
9. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
10. WuXi PharmaTech Announces Second-Quarter 2012 Results
11. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... GABLES, Fla. , Nov. 20, 2014   ... to become the first U.S. commercial producer of Molybdenum-99 ... a contract with INVAP to design its ... Fla. Mo-99 is the parent isotope of ... medicine procedures worldwide. In 2012, Congress passed legislation making ...
(Date:11/21/2014)...   Wellcentive , the industry leader in ... announced today being named one of the four ... .  Sponsored by Intel, the world leader in ... recognizes companies developing leading-edge technology and unique approaches ... Wellcentive,s Mason Beard , senior ...
(Date:11/21/2014)... 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... offering of $80,000,000 aggregate principal amount of 5.25% Convertible ... private offering within the United States ... buyers pursuant to Rule 144A under the Securities Act ... also granted the initial purchasers an option to purchase ...
Breaking Medicine Technology:Coqui RadioPharmaceuticals Inks Deal With INVAP 2Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Lexicon Announces Pricing Of Convertible Senior Notes Offering 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 3
... Results Reported at American Association for Dental Research ... Parion Sciences, Inc., a,privately-held, development-stage pharmaceutical company dedicated ... body,s mucosal,defenses, today announced preliminary results from a ... channel blocker, P-552-02, as a topical,therapy for dry ...
... April 7 A biosimilar product for,treating the ... the,white blood cells of patients is safe and ... a reference,product. This is the result of a ... company Kwizda Pharma GmbH and the Indian manufacturer,INTAS ...
Cached Medicine Technology:Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment 2Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment 3Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 2Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 3
(Date:11/22/2014)... Sandbridge Capital, a private equity ... consumer brand sector, acquired a minority stake in ... to help fund BackJoy’s global growth and accelerate ... proprietary apparel and footwear lines. Sandbridge Capital Managing ... Directors. , BackJoy is a high-growth health and ...
(Date:11/22/2014)... Columbus, OH (PRWEB) November 22, 2014 ... trials for AndroGel side-effects lawsuits have been scheduled ... District Court, Northern District of Illinois. U.S. District Judge ... litigation, issued a Case Management Order (CMO) on November ... as deadlines for attorneys to submit documents and other ...
(Date:11/22/2014)... News) -- Those air-blown hand dryers in public restrooms ... a new study suggests. British researchers placed a ... in order to simulate poorly washed hands. They then ... paper towels to dry their hands. The investigators ... germs around both types of dryers than around towel ...
(Date:11/21/2014)... Haven, CT (PRWEB) November 21, 2014 ... added a veteran radio industry sales professional to its ... Disney, brings 30 years of leadership and sales experience ... office and assume the title of Director of Strategy ... and Development, Robert O’Mara. , Heinemann will handle a ...
(Date:11/21/2014)... 2014 (HealthDay News) -- The cost of diabetes care ... recent years, climbing to more than $322 billion annually, ... cost were seen with prediabetes care, which have risen ... percent, the researchers added. In 2012, excess medical ... than $1,000 for every American. That total includes $244 ...
Breaking Medicine News(10 mins):Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2Health News:Radio Industry Veteran Joins CRN International’s Sales Organization in Detroit 2Health News:Cost of Diabetes Care Keeps Climbing, Report Shows 2
... following ace cricketer Sachin Tendulkar's and several other players complaining ... the sports arena//. ,Tennis elbow, or lateral epicondylitis ... where the outer part of the elbow becomes painful and ... or a direct bang. The problem occurs following overuse of ...
... with type-2 diabetes are at high risk of ... events are the main reason for their decreased ... of peroxisome proliferator-activated receptor-? (PPAR-?) could reduce macrovascular ... treat type-2 diabetes. ,A recent study, published ...
... an independent risk factor for cardiovascular disease in both ... fold relative to nondiabetic subjects and that 80 percent ... of an atherosclerotic event//. In these patients ... and so the presence of even borderline-high-risk LDL-C signals ...
... capable of altering the emotional state of humans. Physiological ... in folk medicine and aromatherapy for a long time//. ... mood enhancing properties by aromatherapists. ,Recently a study, ... & Behavior, was undertaken to investigate the impact of ...
... the benefits of oral ZYVOX for the treatment of ... compared data from 80 health care clinics and compared ... The results show that oral tablets of Linezolid (ZYVOX), ... to health clinics compared to vancomycin. ,This ...
... have reconstructed defective windpipes using tissue engineering in ... growing the sections of cartilage tube // and ... they were in the womb. This technique of ... Undifferentiated stem cell from amniotic fluid, which is ...
Cached Medicine News:Health News:Tennis elbow not new among cricketers, say experts 2Health News:Aromatherapy: Ambient odors of orange and lavender reduce anxiety 2Health News:Oral use of ZYVOX (Linezolid) is better to Intravenous Vancomycin use for Skin Infections 2
... is a SmartBeam platform providing high-performance scanning and ... most vital clinical sites - spine and femur ... ,The full-function DPX Bravo densitometer gives you a ... You can place it in almost any room ...
... System consists of the portable AutoPulse Platform, ... rechargeable battery pack with a state-of-the-art recharger. ... adults with weight up to 300 lbs ... inches (76 to 130 cm) and chest ...
... is an integrated system that will perform ... want it. You no longer need to ... arterial inflow with and without reactive hyperemia ... the time for measurements and the frequency ...
... System combines cutting edge technology with proven Hokanson ... package available in the US and Canada. ,The ... to do vascular examinations in the same order ... waveforms and data in a database. Tests are ...
Medicine Products: